JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer

被引：10
|
作者：
Sivanandhan, Dhanalakshmi [1 ]
Rajagopal, Sridharan [1 ]
Nair, Sreekala [2 ]
Basavaprabhu, B. [2 ]
Dhkar, Reshma [2 ]
Viswakarma, Santosh [2 ]
Siddiqui, Amir [2 ]
Zainuddin, Mohd [2 ]
Rudresh, G. [2 ]
Daram, Prashanthi [2 ]
Mohire, Sunil [2 ]
Krishnakumar, V [2 ]
机构：
[1] Jubilant Therapeut Ltd, Yardley, PA USA
[2] Jubilant Biosys Ltd, Bangalore, Karnataka, India
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-1756
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1756
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
    Shirbhate, Ekta
    Singh, Vaibhav
    Jahoriya, Varsha
    Mishra, Aditya
    Veerasamy, Ravichandran
    Tiwari, Amit K.
    Rajak, Harish
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 263
  • [22] Effects of a novel HDAC6-selective inhibitor's radiosensitization on cancer cells
    Hu, Huixiao
    Wang, Qi
    Zhang, Yuni
    Yang, Shuhua
    Shen, Aihua
    Yan, Junfang
    Zhao, Denggao
    Hu, Burong
    MOLECULAR BIOLOGY REPORTS, 2024, 51 (01)
  • [23] Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells
    Bulut, Ipek
    Lee, Adam
    Cevatemre, Buse
    Ruzic, Dusan
    Belle, Roman
    Kawamura, Akane
    Gul, Sheraz
    Nikolic, Katarina
    Ganesan, A.
    Acilan, Ceyda
    CANCERS, 2022, 14 (23)
  • [24] A Novel Dual HDAC6 and Proteasome Inhibitor Elicits Outstanding Cytotoxicity Against Multiple Myeloma
    Teng, Fang
    Liu, Lanting
    Sun, Hao
    Zhang, Xiaoyu
    Sun, Xiyue
    Yu, Zhen
    Qiu, Lugui
    Hao, Mu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S190 - S190
  • [25] Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent
    Ojha, Ritu
    Chen, I-Chung
    Hsieh, Chien-Ming
    Nepali, Kunal
    Lai, Row-Wen
    Hsu, Kai-Cheng
    Lin, Tony Eight
    Pan, Shiow-Lin
    Chen, Mei-Chuan
    Liou, Jing-Ping
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (24) : 17824 - 17845
  • [26] Preclinical evaluation of a novel LSD1 inhibitor SYHA1807 for the treatment of small cell lung cancer
    Wu, Lingyun
    Yang, Hanyu
    Zhao, Lele
    Sun, Jianjun
    Liu, Jian
    Xia, Yuanfeng
    Chan, Chichung
    Chen, Shuhui
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Lipidomic profiling reveals lipid regulation by a novel LSD1 inhibitor treatment
    Li, Yan
    Qian, Xinying
    Lin, Yiyun
    Tao, Lei
    Zuo, Zeping
    Zhang, Huaqin
    Yang, Shengyong
    Cen, Xiaobo
    Zhao, Yinglan
    ONCOLOGY REPORTS, 2021, 46 (05)
  • [28] JBI-778, a novel brain-penetrant small molecule PRMT5 inhibitor for treatment of cancer
    Sivanandhan, Dhanalakshmi
    Gajendran, Chandru
    Sadhu, Naveen M.
    Mohammed, Zainuddin
    Gosu, Ramachandraiah
    Sher, Divsha
    Mansur, Shahar
    Friedmann-Morvinski, Dinorah
    Rajagopal, Sridharan
    Rastelli, Luca
    CANCER RESEARCH, 2023, 83 (07)
  • [29] Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer
    Xiao, Kai
    Li, Yuan-Pei
    Wang, Cheng
    Ahmad, Sarah
    Vu, Michael
    Kuma, Krishneel
    Cheng, Yi-Qiang
    Lam, Kit S.
    BIOMATERIALS, 2015, 67 : 183 - 193
  • [30] Design and development of a novel series of HDAC6-selective inhibitors for the treatment of cancer
    Shuttleworth, Stephen J.
    CANCER RESEARCH, 2014, 74 (19)
12345